FiercePharma: Drugmaker Eli Lilly nears another settlement over its antipsychotic drug Zyprexa

Twelve state Zyprexa lawsuits remain outstanding, a spokesman told the Health Blog, and this latest settlement effort would wrap up a “subset” of that number.

Tracy Stanton
Fierce Pharma
July 23, 2009

Eli Lilly is close to settling another slate of Zyprexa marketing cases. According to the company’s quarterly report, it’s in “advanced discussions” with attorneys general investigating the company for off-label promotions of the antipsychotic drug. Lilly took a $105 million charge against earnings in anticipation of a settlement, the Wall Street Journal Health Blog reports.

This settlement would be the latest in a series. Lilly’s marketing practices on Zyprexa have drawn scrutiny from states and the feds. Some of those probes were settled earlier this year when Lilly agreed to pay $1.42 billion to the U.S. Justice Department and a number of states. Previously, the company had pledged to pay $1.2 billion to plaintiffs in liability suits, and another $77 million or so to 33 states, including Alaska.

Read entire article: